Use este identificador para citar ou linkar para este item: http://repositorio.ufc.br/handle/riufc/25243
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorPaula, Paulo C.-
dc.contributor.authorSousa, Daniele de Oliveira Bezerra de-
dc.contributor.authorOliveira, José Tadeu Abreu de-
dc.contributor.authorCarvalho, Ana Fontenele Urano-
dc.contributor.authorAlves, Bella Giselly Torres-
dc.contributor.authorPereira, Mirella L.-
dc.contributor.authorFarias, Davi F.-
dc.contributor.authorViana, Martonio P.-
dc.contributor.authorSantos, Flavia A.-
dc.contributor.authorMorais, Talita C.-
dc.contributor.authorVasconcelos, Ilka M.-
dc.date.accessioned2017-08-30T10:34:19Z-
dc.date.available2017-08-30T10:34:19Z-
dc.date.issued2017-
dc.identifier.citationPAULA, P. C. et al . A Protein isolate from Moringa oleifera leaves has hypoglycemic and antioxidant effects in Alloxan-induced diabetic mice. Molecules, Basel, v. 22, p. 1-15, 2017.pt_BR
dc.identifier.issnISSN: 1420-3049-
dc.identifier.urihttp://www.repositorio.ufc.br/handle/riufc/25243-
dc.language.isoenpt_BR
dc.publisherMoleculespt_BR
dc.subjectMoringapt_BR
dc.subjectAlloxanpt_BR
dc.subjectAloxanopt_BR
dc.subjectAntioxidantespt_BR
dc.titleA protein isolate from Moringa oleifera leaves has hypoglycemic and antioxidant effects in Alloxan-induced diabetic micept_BR
dc.typeArtigo de Periódicopt_BR
dc.description.abstract-ptbrMoringa oleifera has been used in traditional medicine to treat diabetes. However, few studies have been conducted to relate its antidiabetic properties to proteins. In this study, a leaf protein isolate was obtained from M. oleifera leaves, named Mo-LPI, and the hypoglycemic and antioxidant effects on alloxan-induced diabetic mice were assessed. Mo-LPI was obtained by aqueous extraction, ammonium sulphate precipitation and dialysis. The electrophoresis profile and proteolytic hydrolysis confirmed its protein nature. Mo-LPI showed hemagglutinating activity, cross-reaction with anti-insulin antibodies and precipitation after zinc addition. Single-dose intraperitoneal (i.p.) administration of Mo-LPI (500 mg/kg·bw) reduced the blood glucose level (reductions of 34.3%, 60.9% and 66.4% after 1, 3 and 5 h, respectively). The effect of Mo-LPI was also evidenced in the repeated dose test with a 56.2% reduction in the blood glucose level on the 7th day after i.p. administration. Mo-LPI did not stimulate insulin secretion in diabetic mice. Mo-LPI was also effective in reducing the oxidative stress in diabetic mice by a decrease in malondialdehyde level and increase in catalase activity. Mo-LPI (2500 mg/kg·bw) did not cause acute toxicity to mice. Mo-LPI is a promising alternative or complementary agent to treat diabetes.pt_BR
Aparece nas coleções:DMC - Artigos publicados em revistas científicas

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
2017_art_ppc.pdf4,22 MBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.